Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC at Needham Neuroscience Forum (Virtual) Transcript

Mar 16, 2022 / 05:05PM GMT
Release Date Price: $158.33 (+2.33%)
Ami Fadia
Needham & Company, LLC, Research Division - Research Analyst

Good afternoon, everyone. Welcome to our session with Jazz. It's my pleasure to be hosting the Jazz team with Bruce Cozadd, who is the Chairman and CEO of the company; along with his R&D leadership team. We've got Robert Iannone, who is the Head of Research and Development; Phil Jochelson who's the Head of Neuroscience Development and Joshua Stadelmann, who's the Vice President of neuropsychiatry.

Perhaps I would request Bruce to kick us off with a few opening remarks, and we can take it from there. Before I let you start, Bruce, just for the audience, if you have any questions along the way that you'd like me to ask, please feel free to send it over in the chart. With that, Bruce?

Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO

Great, Ami, and thank you for having us today. It's nice to be able to dive into 1 area of our pipeline with a little more specification. Before we get going, I do want to note that no forward-looking statements, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot